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Abstract
Background: Next generation sequencing (NGS) provides a key technology for deciphering the genetic
underpinnings of human diseases. Typical NGS analyses of a patient depict tens of thousands non-reference coding
variants, but only one or very few are expected to be significant for the relevant disorder. In a filtering stage, one
employs family segregation, rarity in the population, predicted protein impact and evolutionary conservation as a
means for shortening the variation list. However, narrowing down further towards culprit disease genes usually
entails laborious seeking of gene-phenotype relationships, consulting numerous separate databases. Thus, a major
challenge is to transition from the few hundred shortlisted genes to the most viable disease-causing candidates.
Results: We describe a novel tool, VarElect (http://ve.genecards.org), a comprehensive phenotype-dependent
variant/gene prioritizer, based on the widely-used GeneCards, which helps rapidly identify causal mutations with
extensive evidence. The GeneCards suite offers an effective and speedy alternative, whereby >120 gene-centric
automatically-mined data sources are jointly available for the task. VarElect cashes on this wealth of information, as
well as on GeneCards’ powerful free-text Boolean search and scoring capabilities, proficiently matching
variant-containing genes to submitted disease/symptom keywords. The tool also leverages the rich disease and
pathway information of MalaCards, the human disease database, and PathCards, the unified pathway (SuperPaths)
database, both within the GeneCards Suite. The VarElect algorithm infers direct as well as indirect links between
genes and phenotypes, the latter benefitting from GeneCards’ diverse gene-to-gene data links in GenesLikeMe.
Finally, our tool offers an extensive gene-phenotype evidence portrayal (“MiniCards”) and hyperlinks to the parent
databases.
Conclusions: We demonstrate that VarElect compares favorably with several often-used NGS phenotyping tools,
thus providing a robust facility for ranking genes, pointing out their likelihood to be related to a patient’s disease.
VarElect’s capacity to automatically process numerous NGS cases, either in stand-alone format or in VCF-analyzer
mode (TGex and VarAnnot), is indispensable for emerging clinical projects that involve thousands of whole
exome/genome NGS analyses.
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Background
There is increasing recognition by the scientific commu-
nity that next generation sequencing (NGS) is a pivotal
technology for diagnosing the genetic cause of many hu-
man diseases. This acknowledgment is taking form in
several large-scale projects which implement NGS as a
key instrument for elucidating the genetic components
of rare diseases and cancer [1]. Other clinical studies
aimed at deciphering monogenic and complex dis-
eases have also demonstrated the effectiveness of
various NGS approaches such as whole genome se-
quencing, whole exome and gene panel sequencing,
as exemplified in [2–6].
Primary analysis of disease NGS results includes se-
quence read mapping and variant calling, with results
stored in a Variant Call Format (VCF) file. The VCF file
typically contains ~20,000-50,000 positions that differ
from the reference genome (“variant long list”). Subse-
quently, analysis pipelines sift these SNPs and indels by
populating the VCF file with annotation data, such as
segregation in affected families, genetic linkage informa-
tion [7], population frequency [8] and missense protein
impact as exemplified by PolyPhen [9] SIFT [10] and
SNAP2 [11], all facilitating variant filtration (secondary
analysis). This helps generate a “variant medium list”,
with a few dozen to a few hundred entries, depending
on the assumed mode of inheritance and on the
employed filtering cutoffs.
In the foregoing analyses, variants are analyzed with-
out regard to the disease phenotype of the sequenced
individual. As a first step in introducing phenotype rela-
tionships, many pipelines utilize knowledge on variant-
disease relations (e.g. ClinVar [12] or COSMIC [13]) for
further filtration of the sequence variants.
A typical gene can have a multitude of variants that
have not yet been documented to have a relationship
with a disease or a phenotype. So in most cases, none of
the annotated variant-disease relations appear relevant
to the sequenced subject. Furthermore, it has been
shown that every genome harbors about 100 loss of
function variants with about 20 genes completely inacti-
vated [14], so frequency and impact filtering is not suffi-
cient to identify causative variants. To address these
challenges, a gene-based interpretation process becomes
necessary. The strategy entails finding disease or pheno-
type relationships for the gene and not for the variant
contained within it.
In this paper, we describe the construction and use of
VarElect (ve.genecards.org), a free web-based phenotype-
dependent NGS variant prioritizer, which leverages the
wealth of information in GeneCards and its affiliated da-
tabases [15–19] (Fig. 1). VarElect employs GeneCards’
powerful search and scoring capacities, and its algorithm
affords inferring direct as well as indirect links between
sequenced genes and disease/symptom/phenotype key-
words. The indirect links benefit from GeneCards’ excel-
lent capacity to relate genes to each other via numerous
annotations. VarElect thus provides a robust facility for
ranking genes and pointing out their likelihood to be re-
lated to a patient’s disease.
Methods
Scoring
The scores included in VarElect results basically stem
from Elasticsearch technology [20]. The score of a
specific term is determined by the frequency of its
appearance in the individual GeneCard, as compared to
that in all genes (inverse document frequency correc-
tion). While Lucene-based search mechanisms such as
Elastic and Solr might cause various biases, e.g. depend-
ence on how in-depth a topic is studied and published,
Solr search is commonplace in semantic retrieval and
navigation in scientific document collections (cf [21]).
Further, boosting factors are applied in VarElect for im-
portant sections (e.g. Disorders or Function) reflecting
the greater significance attributed to gene-phenotype
connections found via these annotations. For Boolean
multi-word searches, the complete query is first sent to
the search engine to determine the set of genes that
match the complete Boolean query. For such genes, the
query is then broken into search terms (single word or
quoted multiple words), each scored independently, and
the individual scores are summed.
In the indirect mode, scores include both the strength
of the relationship AB between gene A (implicated) and
gene B (implicating) as well as the strength of the rela-
tionship BP between gene B and phenotype P. The
former scores are obtained from a pre-computed gene-
to-gene matrix, constructed based on all pairwise gene-
symbol search relationships in the GeneCards database.
This indicates the propensity of gene A’s symbol within
Fig. 1 VarElect information flow. Variants-containing genes are
mapped by VarElect, in an example, to two OR-ed phenotype
keywords. In the direct mode, Gene A is directly related to
phenotype 1. In the indirect mode, Gene D is related to both
Phenotype 1 and Phenotype 2. The three implicating genes R, S
and T generate Gene-Gene-phenotype connections as shown via
three GeneCards sections
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the GeneCard of gene B, e.g. in summaries, publications,
pathways, interactions or paralogy relations. The final





The summation is for up to five B genes (cf. [22])
with the highest compound ABxBP scores. F is a
normalization factor that affords a comparison be-
tween direct and indirect scores, facilitating a capacity
to generate a unified (interlaced) record of direct and
indirect genes. We currently use F = 0.05, a value de-
rived by running a sample set of 500 genes with 500
different phenotype terms, of which 294 queries had
both direct and indirect results, and calibrating F to
show a good balance between the direct and indirect
scores (Additional file 1: Figure S1).
Interlacing of direct and indirect results
In Additional file 1: Figure S1, the score computed by
the equation below, and shown as blue line, ranges
from 0 to 1. The value 0 means all direct results
come before all indirect results, and 1 is the reverse
situation where all indirect results come before all
direct results. The score is calculated by counting the
number of changes needed to get the sorted score
from a perfect separation (0 situation) and dividing
by the maximum number of changes – the number
of changes needed to reach a perfect reverse order (1
situation) - where a change is only a replacement of




rn þ ND−nð Þ
 !
= ND  N1ð Þ
where ND is the number of direct items, NI is the num-
ber of indirect items and rn is the internal item rank,
separate for the direct and indirect lists (the internal
order of the direct/indirect results is not affected by the
factor).
Benchmarking queries
In order to test VarElect’s performance against Phenolyzer
[23], we generated 34 benchmark queries, composed of a
disease causing gene (the probe gene) and its relevant dis-
ease/phenotype/symptom terms. Of these, 13 queries were
based on in-house exome analyses, 9 were based on
exomes analyzed at Toldot (http://www.toldot-dna.com/
content/about-us), 12 from published literature, including
4 recorded in MalaCards. In the VarElect runs, each
probe gene was accompanied by background genes,
some consisting of filtered gene lists from the original
experiment, and others including groups of 500 ran-
domly sampled genes from the Illumina TruSight
whole exome gene panel (http://www.illumina.com/
products/trusight-one-sequencing-panel.html) (see Add-
itional file 2: Table S1 for more details).
For comparison of VarElect’s against Exomiser [24], 10
real pathological variants from solved in-house exomes
were spiked (each one separately) into the demo VCF
file that is distributed with Exomiser (“Pfeiffer.vcf”, after
removal of the originally spiked variant). These VCF files
were analyzed using hiPHIVE - an algorithm for cross-
species phenotype analysis in whole-exome candidate
gene prioritization [24], using the command line tool of
Exomiser (V 7.1). The following parameters were used:
prioritiser = hiPHIVE -F 2 -Q 30 –P true. As routinely
done when using Exomiser, a restricted vocabulary tool,
the submitted disease-related terms were translated to
Human Phenotype Ontology (HPO) terms using Phe-
nomizer (http://compbio.charite.de/phenomizer/). The
analysis output included 715 variants from 607 genes.
The same genes were submitted in parallel to VarE-
lect using the original (untranslated) disease-related
terms for gene prioritization (submission details in
Additional file 3: Table S2).
For comparison of VarElect against Phevor2 [25],
the same data used for Exomiser were submitted to
Omicia Opal 4.16.1, using the VAAST3 filtering and
prioritization pipeline [26]. Spiked VCF files were
uploaded into Omicia commercial cloud application,
the variants were then annotated, filtered and scored
by VAAST tool version 3.0.3.6. VAAST results were
further submitted for gene phenotype prioritization by
Phevor 2.0.0 (with the same phenotypes as used by
VarElect). The genes that passed the VAAST proced-
ure were also submitted to VarElect. Spiked genes
that were filtered out by VAAST (3 cases) were sub-
sequently added manually to the gene list submitted
to VarElect.
For comparison of VarElect against Ingenuity (IVA),
the same data used for Exomiser were submitted to ana-
lysis in IVA. The IVA default filtration pipeline was used.
Biological context setting was first selected as 0-hops
from the relevant phenotype terms as translated by In-
genuity Pathway Analysis (IPA). If the spiked gene was
not included in the list of kept genes, then the biological
context filter was reset to “within 1 hop”. The gene list
which included the spiked gene was submitted in paral-
lel to VarElect using the original disease-related terms
for gene prioritization in both the direct and indirect
mode.
Results and discussion
VarElect’s basic functionality as a web tool entails speci-
fying a gene symbol list imported from an experimental
data file(s), together with disease phenotype and symp-
tom terms related to the studied disorder (Fig. 2a).
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Genes are typically imported from a VCF file of an NGS
experiment, with additional sources including lists of
genes differentially expressed in transcriptome studies or
those with significant variants in genome-wide associ-
ation studies. VarElect then generates a scored gene list
that helps the user select the best disease-causing gene
candidates.
VarElect input
In the gene entry process, one can supply a list of up
to 4000 genes, with unlimited count in a version
coming soon. VarElect provides a “symbolization” tool
which validates that the input genes are official sym-
bols (Fig. 2b). Whenever possible, non-symbol identi-







Fig. 2 VarElect interface and direct mode example. a The user enters two types of input: gene symbol list and phenotype expression. A
Symbolize button activates a process whereby correct symbols are assigned. The phenotype phrase undergoes automatic syntactic validation,
whereby success is indicated by a green ✓ check mark. Example cases at top enable initial familiarization with the VarElect tool. “My Analyses”
store previous analyses that may be accessed by the “Open” button. b Top, “identified” genes for which correct official symbols have been
entered and are ready for analysis. Symbols may be removed at will from the input list using the X icon. Bottom, the “unidentified” tab displays
cases which require symbol resolution. Suggested symbols may be selected from the drop down menu or alternate symbols may be searched for
in GeneCards with the magnifying glass or entered using the edit icon. c Output results presented in two tabs for direct and indirect modes.
Each result row displays a gene along with its basic information, such as the gene description, category and the phenotype relevance score, also
indicated by the size and color of the bar. “Matched Phenotypes” and “Matched Phenotype Count” columns appear for multi-term search phrases.
Results may be sorted by any of the table columns but are ranked by the relevance score by default. Gene symbols link to the relevant GeneCard,
the orange icon to the variants section of the same gene and the yellow icon to a MalaCards search for the gene symbol. Entering strings within
the filter text box searches for them within any of the result rows. The question marks in each column provide additional information. d An
expanded row displays a”MiniCard” with snippets from various webcard sections, which place the exhibited evidence in context, highlighting the
search words that received hits for one of the genes. External links enable further scrutiny of the information in the data sources from which it
was received
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into the corresponding official symbol. This capacity
is based on the comprehensive gene alias portrayal of
GeneCards [15].
The phenotype-related keywords entry is free-text,
without any limitation to a closed list of terms or to an
ontology. This makes it especially suited for searches of
rare, unique and relatively uncharacterized medical ter-
minology in the process of deciphering the genetic cause
of the disease or exhibited symptom/phenotype. Such a
capacity relies on the vast amounts of information
within VarElect’s data sources in the GeneCards Suite
(see VarElect knowledgebase). Phenotype entry process-
ing incorporates real-time syntactical analysis, including
a check of the Boolean logic.
Boolean searches in VarElect are especially useful in
two specific scenarios, which are quite prevalent in
disease NGS phenotype-based interpretation. The first is
cases in which a patient is afflicted with a disorder
describable by many different synonymous terms (e.g.
“paraplegia”, “paraparesis”, “lower limb paralysis”, “lower
extremities paralysis”). In such a case, the user would
clearly wish to encompass all possibilities, and hence is
advised to use an all-OR search string. The second case
involves an attempt to single out a syndrome that con-
comitantly has several symptoms (e.g. “mental retard-
ation”, “facial dysmorphism”, “ataxia”). In such cases,
using all-AND is obviously advised.
VarElect results and scoring
At the analysis stage, VarElect searches the bag-of-words
associated with the entire GeneCard for each gene in the
list, against the entered phenotype keywords. In doing
so, it relies on GeneCards’ powerful search engine, and
also leverages the extensive information in GeneCards.
This includes key data present in the entire GeneCards
knowledgebase, which automatically mines data from
more than 120 sources [15, 27]. Some of the GeneCards
suite-member-specific sources include MalaCards, the
human disease database which encompasses ~17,000
disease entries from 15 main sources [17, 18]; Path-
Cards, which consolidates 12 human biological pathway
sources into ~1000 SuperPaths based on shared gene
content [19]; and LifeMap Discovery, with its manually
curated gene expression information on tissues and cells,
including the realms of embryonic development and
stem cells [28].
The results of VarElect analyses are shown as a
table of genes with decreasing phenotype relation
scores (See Methods). The gene list may also be
sorted by the count of phenotype term hits in cases
of multi-word search expressions. The results are
shown in two separate tabs, one for genes with direct
phenotype relations, and the other for those with in-
direct connection to the phenotype terms. The latter
analyses are in the realm of “guilt by association”,
whereby gene A has no connection to the phenotype,
but (in an example) gene A and gene B belong to the
same pathway, and gene B is related to the phenotype
(Fig. 1, Fig. 2c). Gene B is defined as an “implicating
gene” for the indirect relationships between gene A
(the implicated gene) and the phenotypes.
In order to enhance user insight, contextual evidence
is displayed as “MiniCards”, in full analogy to such fea-
ture in GeneCards [15]. The MiniCards display the evi-
dence for gene-keyword connection in the form of
snippets from various sections of the relevant GeneCard
or MalaCard [15], as well as hyperlinks to GeneCards
Suite sources for further scrutiny. For direct mode, there
is a single-tier MiniCards display (Fig. 2d). The indirect
mode has two tiers of evidence: the first (Fig. 3a) shows
up to 5 implicating genes for every implicated gene, and
the second (Fig. 3c), displays MiniCards with phenotype
relations for each of the 5 implicating genes.
While inter-gene score comparison is legitimate in
out tool, scores resulting from different phenotype
term searches cannot be readily compared at present.
In an upcoming version, VarElect will include global
normalization, based on the score distribution of the
same phenotype expression searched within all of
GeneCards. This will allow assigning a nominal P-value
statistic to every VarElect result, even those resulting from
complex Boolean queries. We will also take into account
the length of the submitted gene list, analogous to mul-
tiple testing counts.
VarElect reports and integration
Excel reports
VarElect exports search results into an Excel file with
multiple worksheets that organize the scored gene list
into direct and indirect results. In the indirect work-
sheet, each implicated gene is presented with several
rows for its implicating genes, along with their corre-
sponding scores. All columns are faithfully depicted in
the output files, except for MiniCards which are only
available via the web interface.
TGex and VarAnnot
For users that prefer to perform the analysis in the con-
text of a VCF file, VarElect has two alternative input–
output mechanisms. The first is the TGex (Translational
Genomics Expert) platform, designed to consolidate nu-
merous annotation attributes obtained via the input of a
VCF file, along with VarElect interpretation scores
(based on inputted phenotypes) to a single user view
with elaborate analysis parameter control. TGex gener-
ates reports in flexible formats, allowing VCF-to-clinic
analyses. The second is the VarAnnot plugin, which per-
forms a limited subset of the aformentioned analyses
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within a VCF-type Excel sheet. VarAnnot outputs the
phenotype-gene scores into new columns. The VarElect
interpretation scores in both tools can undergo joint
filtering with other VCF annotation columns.
Integration with NGS platforms
VarElect can also be integrated into primary and second-
ary analysis platforms or pipelines, which can benefit
from enhanced phenotype interpretation capacities. This
option offers both front-end and back-end application
programming interfaces (APIs). The back-end API allows
integrators to have better control over the interaction with
VarElect within their tool, and is best leveraged when the
integrating platform has secondary analysis capabilities.
The front-end API allows for running a skinny version of
VarElect’s web-based user interface embedded within the
integrator’s analysis platform, best serving platforms that
end their analysis after creating the VCF file. One such
example of integration is with the Lab7 LIMS system
(https://www.lab7.io/).
VarElect knowledgebase
Herein we note some special points of strength of the
GeneCards Suite databases and tools, which underlie
VarElect capacities:
MalaCards
MalaCards is a disease-centric database, with extensive
information on each of >17,000 disease entries [17, 18].
Each disease is connected to a list of genes, with em-
phasis on a gene subset with especially strong disease re-
lations, termed “elite genes”. Key MalaCards sections are
Aliases, Summaries and Symptoms, all rich in searchable
text. GeneCards and VarElect’s searches now support
finding keywords in these three sections. This allows
users of VarElect to perform comprehensive disease-
related searches, relying on the imported MalaCards
annotations. The corresponding search results are
accompanied by MalaCards-based MiniCards and deep
links.
PathCards
For the benefit of VarElect searches, GeneCards contains
not only pathway data [15] but also unified SuperPath
information from PathCards [19]. The reason for con-
structing PathCards is that there is a pronounced het-
erogeneity in pathway naming and gene content in
different original sources. To overcome this shortcoming
we developed an algorithm which unifies pathways into
SuperPaths [19]. This process clusters pathways based





Fig. 3 VarElect information display and indirect mode. a The query information section (top) displays the phenotype phrase, the fact that no
direct hits were found and in a separate tab - the genes found in indirect mode. Links for un-hit genes and the entire submitted symbolized gene
list are also provided. The latter may be reanalyzed by changing the phenotype phrase. b One of the implicated genes expanded to reveal its
(top 5) implicating genes, along with their phenotype scores. c Implicating genes expanded to reveal two types of “MiniCards”. First - “Gene to
Gene Relation”, i.e. evidence showing how the implicated gene TLN1 appears in the GeneCard for the implicating gene IL6. Second, “Gene to
Phenotypes/Keywords Relation” show how the submitted phenotype keywords appear in different sections of the same implicating gene’s
webcard. The provided external links enable further examination of the evidence in the source data itself
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by integrating 3,215 pathways from 12 sources into
1,073, whilst keeping them maximally informative. An
immediate outcome of SuperPath generation is the infer-
ence of new gene connections that were not reported via
any pre-unification pathway, available for VarElect’s gene
to gene inference.
GenesLikeMe
GenesLikeMe, an outgrowth of GeneDecks Partner
Hunter [29], creates relation metrics that quantify the
sharing of common descriptors/attributes among genes.
Most of these gene-gene relationships are embedded
within GeneCards, thus serving the VarElect search in
its indirect mode. These relations include shared path-
ways, shared drugs/compounds, shared protein domains,
shared mouse phenotypes, shared normal tissue expres-
sion patterns (Fishilevich et al. submitted) and shared
publications. Also included are relationships arising from
protein-protein interaction networks and paralogy
groups. GenesLikeMe entails a roadmap for future en-
richment of VarElect’s indirect mode.
VarElect advantages
Post-filtering phenotype interpretation
A central advantage of VarElect is its capacity to perform
post-filtering gene list interpretation and scoring based
on user-entered phenotype keywords. A large number of
NGS analysis pipelines involve step-wise filtering based
on annotation fields in a VCF file or equivalent web dis-
play. Such fields often include data from databases such
as ClinVar [12] and COSMIC [13], which relate variants
to disease names. This approach cannot provide an ul-
timate NGS solution for two reasons. The first is that
not all diseases have defined names, and often a disorder
is described by a combination of phenotype terms, with
partial overlap to disease nomenclature. The second is
that a typical gene can have thousands of variations not
yet documented to have a relationship with any disease,
hence in most NGS-analyzed cases, the called variations
have a relatively low probability of finding variant-
disease relations appearing in the disease variant reposi-
tories. VarElect’s gene centric approach and acceptance
of unrestricted free text phenotype queries, combined
with the power of its knowledgebase to relate terms
within such queries to NGS variant-containing genes, of-
fers a powerful enhancement to the disease-variant
lookup strategy.
Addressing the variant-gene dichotomy
A point of strength for VarElect is its clear definition of
the difference between variant-based and gene-based
analyses. VarElect is defined as a ‘variant/gene prioriti-
zer’ despite the fact that its scoring algorithms are purely
gene based. The assumption is that every analyzed gene
is linked to one or more variants, each with its own im-
pact on the function of encoded protein, as listed in the
annotated VCF file. When viewing the VarElect results
table, a gene is considered as representative of such vari-
ant(s). As mentioned in the Background section, variant
filtering will typically filter out low impact variants,
first and foremost synonymous ones. Consequently, a
VarElect-prioritized gene is rarely associated with
multiple variants. In the event that a gene has more
than one high-impact variant, the use of VarElect in
its basic mode calls for going back to the VCF file to
resolve the issue. In the TGex and VarAnnot modes
(see the ‘VarElect reports and integration’ section) this
process happens naturally as the user is presented
with a variant table that includes both the variant im-
pact and the VarElect gene prioritization score.
Time saved
Numerous users perform NGS interpretation by manual
gene by gene or semi-manual search for relationships to
disease and phenotype terms. For example, this could
involve scrutinizing every post-filtering gene in Gene-
Cards, seeking connections to the appropriate keywords.
Batch processing via GeneALaCart [15] affords consider-
able speed-up but VarElect provides a much faster and
more effective solution, since it performs phenotype key-
word searches in GeneCards for hundreds or even thou-
sands of genes with a push of a button.
Gene count flexibility
VarElect allows the user flexibility in the number of
query genes, providing the freedom of different degrees
of VCF filtering prior to VarElect submission.
Extensive database
The numerous data sources mined by GeneCards and its
suite members account for the myriad of links between
phenotypes and genes that are often unique to VarElect.
Powerful search engine
The Elasticsearch engine utilized by VarElect confers
upon it the speed, efficacy and accuracy in relating genes
to phenotype terms.
True free-text searches
In VarElect, no restrictions are imposed on the
phenotype search words used, casting a much broader
search net than that afforded by tools with restricted
vocabularies.
Boolean logic
This greatly enhances VarElect’s capacity in allowing
the user to choose between focusing and broadening/
generalizing the search process.
Stelzer et al. BMC Genomics 2016, 17(Suppl 2):444 Page 201 of 276
MiniCards evidence
VarElect results are displayed in MiniCards, which show
in detail the phenotype terms hit contexts, along with
the sections in which they reside. Hyperlinks enable
quick access to detailed information in the external
databases.
MalaCards integration
MalaCards data on disease aliases, diverse summaries
and disease symptom lists provide great enrichment of
VarElect’s capacity for phenotype interpretation.
Rich gene-gene links
VarElect’s indirect mode is extensively fortified by nu-
merous sources of information affiliated with the Gene-
sLikeMe facility. An additional strength of this mode is
the capacity of VarElect to find textual appearances of a
gene symbol within the entire text of a GeneCard for an-
other gene. Finally, the interlace feature allows one to
compare the strength of directly and indirectly obtained
phenotype-gene relations.
Comparison to other tools
Phenolyzer
Thirty four benchmarking queries (Methods) were sub-
mitted to both VarElect and Phenolyzer [23]. For the lat-
ter, we used the default web interface parameters, with
the addition of the Mentha Protein Interaction Database.
The rank of the probe gene in the output list was used
for the comparison (Fig. 4a). The results show that
VarElect succeeded in ranking probe genes higher than
Phenolyzer. This is especially marked in cases with
multi-term Boolean phenotype expressions. This advan-
tage may be related in part to two functionality differ-
ences between the tools. The first difference is that
VarElect employs strict AND logic when desired,
whereby only genes found to be related to all entered
terms are included in the result gene list. In order to
demonstrate the strength of this option, some of the
queries were entered into VarElect twice, with OR and
with AND, the latter showing marked rank improvement
(Additional file 2: Table S1). The second difference may
be the fact that VarElect provides a free phenotype term
search, while Phenolyzer utilizes a disease match algo-
rithm for translating a submitted term to (e.g.) HPO
symptoms and OMIM diseases. It appears that in gen-
eral VarElect does better in Boolean query expressions
with several search terms (Additional file 2: Table S1).
Exomiser
Exomiser is a tool for functional annotation and pheno-
type based prioritization of variants from whole-exome
sequencing data. The Exomiser-hiPHIVE algorithm
combines information on the rarity of the variant
and its predicted pathogenicity along with the simi-
larity of the patient’s symptoms to animal (mouse
and fish) models for each candidate gene [24]. We
performed a benchmark test (Methods) examining
the rank of probe genes. VarElect performed better,
both when compared the “Exomiser gene phenotype
score” derived from gene to phenotype relevance
solely and the combined score (Fig. 4b).
Ingenuity variant analysis (IVA)
For generating gene-phenotype relations, this tool em-
ploys a “Biological Context filter” (BCF) component. Only
phenotype terms found within the IPA (Ingenuity Pathway
Analysis) Knowledge Base (http://www.ingenuity.com/
science/platform/content-sources) are allowed. The user
has to define the relevant type of connections between the
Variants/Genes and the phenotype. The user then has to
browse the resulting “Path to Phenotype” network dia-
grams (partially analogous to VarElect’s indirect mode) for
every post-filtering variant, so as to obtain user-
defined relevance assessment. The IVA tool (http://
www.ingenuity.com/products/variant-analysis) does not
supply numerical scores to convey the strength of
variant/gene-phenotype connections. VarElect’s free-
text search and gene-phenotype scoring capacities
thus provide clear advantages, although performing
explicit benchmark comparisons to VarElect was not
readily possible as IVA does not generate scores. An-
other advantage of VarElect over IVA is that the
former involves a much higher degree of automation
in the indirect mode, wherein by a push of a button,
thousands of different potential functional paths are
concomitantly examined without user intervention.
We performed a benchmark test (Methods) based on
the appearance of the target gene in the IVA filtered
gene lists. VarElect performed better, both in the dir-
ect and indirect modes (Fig. 4c).
Phevor
This tool, utilized by Omicia [25] performs phenotype
interpretation via various biomedical ontologies, such as
HPO, Mouse Phenotype Ontology (MPO), Disease
Ontology (DO) or Gene Ontology (GO). As in VarElect’s
direct mode, terms entered by Phevor users are mapped
to genes that are connected to them. These relations are
iteratively expanded to include terms from additional
ontologies, thereupon retrieving and scoring genes far-
ther away from the original nodes, similarly to what’s
provided in VarElect’s indirect mode. Thus, VarElect and
Phevor are comparable in their capacity to identify dis-
ease causing variants in genes not yet shown to be dir-
ectly associated with disease. An advantage of VarElect
is its reliance on a much broader, systematically mined
knowledgebase in the framework of the GeneCards Suite.
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We performed a benchmark test (Methods) examining
the rank of probe genes. VarElect performed better, both
when compared to the VAAST3-PHEVOR2 scores as well
as to the results of the PHEVOR2 phenotype-gene associ-
ation mode (Fig. 4d).
Clinical cases solved by VarElect
To date, VarElect helped solve about two dozen Mendelian
disorders in our collaborations with Israeli medical centers.
Some examples are:
Congenital diarrhea
A 4-year old girl of Middle-Eastern Arab origin presented
with apparently recessive non-syndromic congenital diar-
rhea. Exome sequencing of the patient with secondary
analysis filtration revealed 590 rare homozygous variants
(Additional file 4: Table S3). These were prioritized using
VarElect (Fig. 2), showing five gastrointestinally related
candidate genes. The strongest phenotype implication
for “diarrhea” was for TTC37, a known gene for tricho-
hepatoenteric syndrome, harboring a novel homozygous
damaging missense mutation in an evolutionary con-
served residue, with zero frequency in controls, which
withstood validation. Following the detection of this
mutation, the patient was confirmed as having atypical
syndromic diarrhea. This result emphasize the power of
exome sequencing in providing an effective diagnosis for
a misdiagnose disease, later found to be an atypical
syndrome [30].
Capillary leak syndrome
Systemic Capillary Leak syndrome (SCLS) is a rare
disease characterized by attacks of marked increase in
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Fig. 4 Performance comparison of VarElect to competing tools. a Phenolyzer: Thirty four queries were submitted to analysis in both VarElect and
Phenolyzer (Methods). Each query is based on real results and includes a disease causing gene spiked into background genes, accompanied with
real disease related symptoms that were recorded from the relevant patients (Table S1). The rank of the probe gene is color coded, bottom to
top: top 10, top 11–20, top 21–100, below top 100, not found to be connected to the search terms. b Exomiser: Ten queries were submitted to
both VarElect and Exomiser (Methods). The rank of the probe gene resulting from each query in Exomiser was recorded from 2 different score
types; 1) Exomiser gene phenotype score that is solely derived from gene to phenotype relevance 2) Exomiser general score, combining variant
severity score and gene phenotype score. Ranking results are shown with binning as in Fig. 4a. c Ingenuity: Queries as in Fig. 4b were submitted
to Ingenuity Variant Analysis, and the appearance of the spiked gene in the resultant gene list was examined. For this comparison, Ingenuity
0-hop mode was considered comparable to VarElect direct mode, and Ingenuity 1-hop mode was considered comparable to VarElect indirect
mode. d Phevor: Queries as in Fig. 4b were submitted to Phevor2 in combination with VAAST3 filtering (Methods). Ranking results are shown with
binning as in Fig. 4a
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case, an Israeli family with ten affected individuals,
showing suspected autosomal dominant inheritance
with incomplete penetrance [31]. Exome sequencing
was performed for two affected family members
(Additional file 5: Table S4). Using VarElect for vari-
ant interpretation and submitting 37 post-filtration
genes, with “capillary leak” as the phenotype term, no
direct hits were obtained (Fig. 3). However, within the
2 top indirect candidates we found TLN1, showing a
verified severe stop-gain splice mutation, and encod-
ing a cytoskeletal protein that coordinates endothelial
dynamics. We hypothesize that the mutated protein
could lead, via a dominant-negative model, to aber-
rant endothelial dysfunction.
Apnea, Leigh-like
A female patient presented with syndromic apnea
and was suspected of having atypical Leigh disease.
Other symptoms were brainstem lesion, seizures,
mental retardation, nystagmus, bilateral optic atro-
phy, pulmonary hypertension, and prolonged mechanical
ventilation. Following whole exome sequencing of the
patient and her two healthy parents (Additional file 6:
Table S5), we identified 26 rare homozygous variants in
the patient that were heterozygous in both parents
and passed other standard filtering criteria. Submitting
this gene list to VarElect in relation to the Boolean
phenotype expression ‘apnea OR leigh OR brainstem OR
seizures OR nystagmus OR “optic atrophy” OR hyperten-
sion’, the top gene in direct mode was NDUFAF2, harbor-
ing a loss of the start codon [32]. This gene encodes a
mitochondrial complex I assembly factor. Mutations in
this gene are known to cause Leigh syndrome (MIM
256000), which only in rare cases is associated with infantile
apnea [33].
Arthrogryposis multiplex congenita
An Israeli-Druze family with several members pre-
senting with Arthrogryposis Multiplex Congenita
(AMC), characterized by recessive congenital mul-
tiple joint contractures, was studied [34]. Following
whole-exome sequencing of an affected child, variants
remaining post-filtering were subjected to phenotype-
driven prioritization (Additional file 7: Table S6). One
hundred and fifty six homozygous variants were submitted
to VarElect, using “arthrogryposis multiple” as the pheno-
type. The single direct hit revealed a novel variant in a
skeletal muscle protein, with zero frequency in the general
population control databases and correctly segregating
within the extended family. This is a strong candidate
gene for the disease studied.
These four diseases were also subjected to comparative
analysis with the four other phenotype interpretation
tools, as shown in Table 1.
Conclusions
NGS currently revolutionizes disease diagnosis and
treatment, approaching the point of providing a per-
sonal genome sequence for every patient. VarElect,
the free web-based Variant Election GeneCards Suite
member, addresses a central challenge in this process
by performing speedy, comprehensive and highly
accurate phenotype prioritization. The integration of
VarElect into NGS mapping and filtration pipelines
should greatly improve their ability to predict causa-
tive mutations. As such, VarElect emerges as an indis-
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Table 1 Comparative analysis for four diseases with additional phenotype interpretation tools
Target Gene VarElect Phenolyzer Exomiser Phevor (Omicia) Ingenuity
Direct Indirect Direct Indirect
TTC37 1 3 1 1 77
MYBPC 1 2 1 1 1
TLN1 1 0 19 12 58a
NDUFAF2 1 1 1 ND 10
All numbers indicate position in the prioritized list. For Ingenuity, numbers indicate the length of the unprioritized list in which the target gene appears. 0 = not
detected; Direct = direct mode for VarElect, 0-hop for Ingenuity; Indirect = indirect mode for VarElect,> 0-hop for Ingenuity; a = 2-hop; ND not done for technical
reasons. Diseases associated with the listed gene may be viewed in the “Clinical cases solved by VarElect” section
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Additional files
Additional file 1: Figure S1. Merging direct and indirect modes. For
each tested interlacing factor (x-axis) the red line represents the count of
phenotype searches (out of ~300 relevant searches) for which the
highest ranking result was direct (left y-axis). The blue line represents the
average “interlacing score” (right y-axis) of all relevant phenotype
searches. (PDF 52 kb)
Additional file 2: Table S1. Gene lists and corresponding phenotypes
for Phenolyzer. (XLSX 32.0 kb)
Additional file 3: Table S2. Gene lists and corresponding phenotypes
for Phenomyzer and Exomiser benchmarking. (XLSX 16.0 kb)
Additional file 4: Table S3. Vcf file produced from the exome
sequencing of the Congenital Diarrhea clinical case described in the
results section. (GZ 14654 kb)
Additional file 5: Table S4. Two vcf files produced from the exome
sequencing of the Capillary Leak Syndrome clinical case described in the
results section, consisting of the inflicted child as well as cousin.
(GZ 13018 kb)
Additional file 6: Table S5. Three vcf files produced from the exome
sequencing of a trio belonging to the Apnea, Leigh-Like clinical case
described in the results section. (GZ 13334 kb)
Additional file 7: Table S6. Vcf file produced from the exome
sequencing of the Arthrogryposis Multiplex Congenita clinical case
described in the results section. (GZ 1665 kb)
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